Category: allopurinol

Can allopurinol be taken during acute gouty attacks?

Is it safe to continue allopurinol therapy during an acute gout attack, or does it risk worsening the flare?

Acute gout attacks are characterized by painful joint inflammation caused by immune cells attacking urate crystals. While chronic management to lower blood urate levels is crucial for preventing flare-ups, the approach to using urate-lowering therapies such as allopurinol during an acute gout attack continues to evolve. This blog will clarify some of the clinical considerations and evidence surrounding the use of allopurinol during acute gout episodes.

The Dilemma: Traditional Teaching vs. Emerging Evidence. Traditionally, initiating or adjusting allopurinol during an acute attack was discouraged, as altering uric acid levels can exacerbate symptoms. This concept led to a common recommendation of holding off allopurinol until the acute phase subsides. However, recent evidence has challenged this approach, suggesting that allopurinol, if already in use, should be continued during acute attacks to maintain steady uric acid levels and prevent rebound hyperuricaemia.

Continue reading

Improved Patient Education on Adverse Effects of Allopurinol: A Focus on SCAR

The Health Science Authority (HSA) and Agency for Care Effectivness (ACE) in Singapore have recently published a new patient fact sheet on safe usage of allopurinol.

Medical education constantly evolves to meet the needs of patients, and a new allopurinol patient factsheet provides a great example of how better communication can make a significant difference in patient safety and outcomes. This new patient factsheet for allopurinol usage in treating gout will enhance patient safety and the effective management of this painful condition. As a cornerstone in the management of gout, allopurinol has been in use for decades. The new patient factsheet provides clear and accessible information for patients. In particular, it provides important information regarding adverse effects, particularly the rare but serious condition known as Severe Cutaneous Adverse Reaction (SCAR), for patients taking allopurinol.

Continue reading

© 2024 PharmaNUS

Theme by Anders NorenUp ↑

Skip to toolbar